The FDA has accepted the BLA for lecanemab-irmb SC for weekly maintenance dosing in the treatment of early Alzheimer disease.

The Florey Dementia Index (FDI) is valid for predicting the age of onset of mild cognitive impairment (MCI) and Alzheimer disease (AD).

There are disparities in traumatic brain injury (TBI)-related mortality, with the highest rates seen for older adults, men, and non-Hispanic American Indian/Alaska Native persons.

Epilepsy is associated with poor brain health, with a consistent deleterious effect seen on cognitive and motor function and mental health.